How do you see the therapy impacting life expectancy of current and future sufferers?
My pure guess would be that life expectancy won’t change. Therefore, I wouldn’t expect that to be a contributory factor in increasing Daybue users over time.
What is your prediction as to likely market penetration and long-term retention?
Again, my pure guess is that 3,ooo + patients is possible, based on the 6,000+ patient number identified through the healthcare claim study. But that number could well be lower if Anavex’s drug makes it through to approval.
There is likely to be a significant percentage who will not persist with the drug due to side effects (see Mel’s latest post linked below which refers to this) and there are likely to be some who won’t see improvement or won't see sufficient improvement over 6 months to satisfy insurance reimbursement (see PDF example of a Daybue Policy document below).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)